Logo image of GENI

GENIUS SPORTS LTD (GENI) Stock Fundamental Analysis

USA - NYSE:GENI - GG00BMF1JR16 - Common Stock

11.53 USD
-0.26 (-2.21%)
Last: 10/7/2025, 5:13:14 PM
11.5 USD
-0.03 (-0.26%)
After Hours: 10/7/2025, 5:13:14 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to GENI. GENI was compared to 135 industry peers in the Hotels, Restaurants & Leisure industry. GENI has a great financial health rating, but its profitability evaluates not so good. GENI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GENI has reported negative net income.
In the past year GENI had a positive cash flow from operations.
In the past 5 years GENI always reported negative net income.
In multiple years GENI reported negative operating cash flow during the last 5 years.
GENI Yearly Net Income VS EBIT VS OCF VS FCFGENI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

With a Return On Assets value of -8.39%, GENI is not doing good in the industry: 81.48% of the companies in the same industry are doing better.
GENI has a Return On Equity of -10.81%. This is comparable to the rest of the industry: GENI outperforms 43.70% of its industry peers.
Industry RankSector Rank
ROA -8.39%
ROE -10.81%
ROIC N/A
ROA(3y)-14.16%
ROA(5y)-22.16%
ROE(3y)-19.14%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
GENI Yearly ROA, ROE, ROICGENI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

GENI has a worse Gross Margin (23.57%) than 82.22% of its industry peers.
The Profit Margin and Operating Margin are not available for GENI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GENI Yearly Profit, Operating, Gross MarginsGENI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

8

2. Health

2.1 Basic Checks

GENI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GENI has been increased compared to 1 year ago.
GENI has a better debt/assets ratio than last year.
GENI Yearly Shares OutstandingGENI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M 200M
GENI Yearly Total Debt VS Total AssetsGENI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 7.38 indicates that GENI is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.38, GENI belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
There is no outstanding debt for GENI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.38
ROIC/WACCN/A
WACC9.3%
GENI Yearly LT Debt VS Equity VS FCFGENI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

GENI has a Current Ratio of 2.36. This indicates that GENI is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 2.36, GENI belongs to the best of the industry, outperforming 89.63% of the companies in the same industry.
GENI has a Quick Ratio of 2.36. This indicates that GENI is financially healthy and has no problem in meeting its short term obligations.
GENI's Quick ratio of 2.36 is amongst the best of the industry. GENI outperforms 91.11% of its industry peers.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2.36
GENI Yearly Current Assets VS Current LiabilitesGENI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.42% over the past year.
GENI shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.76%.
GENI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.82% yearly.
EPS 1Y (TTM)18.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)25.76%
Revenue growth 3Y24.82%
Revenue growth 5YN/A
Sales Q2Q%24.38%

3.2 Future

Based on estimates for the next years, GENI will show a very strong growth in Earnings Per Share. The EPS will grow by 44.95% on average per year.
Based on estimates for the next years, GENI will show a quite strong growth in Revenue. The Revenue will grow by 16.61% on average per year.
EPS Next Y30.31%
EPS Next 2Y56.84%
EPS Next 3Y44.95%
EPS Next 5YN/A
Revenue Next Year26%
Revenue Next 2Y21.49%
Revenue Next 3Y19.99%
Revenue Next 5Y16.61%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GENI Yearly Revenue VS EstimatesGENI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
GENI Yearly EPS VS EstimatesGENI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GENI. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 92.83 indicates a quite expensive valuation of GENI.
Based on the Price/Forward Earnings ratio, GENI is valued a bit more expensive than 66.67% of the companies in the same industry.
GENI is valuated expensively when we compare the Price/Forward Earnings ratio to 23.36, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 92.83
GENI Price Earnings VS Forward Price EarningsGENI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GENI Per share dataGENI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GENI does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as GENI's earnings are expected to grow with 44.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.84%
EPS Next 3Y44.95%

More info and screens

0

5. Dividend

5.1 Amount

GENI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENIUS SPORTS LTD

NYSE:GENI (10/7/2025, 5:13:14 PM)

After market: 11.5 -0.03 (-0.26%)

11.53

-0.26 (-2.21%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners95.87%
Inst Owner Change0%
Ins Owners8.59%
Ins Owner ChangeN/A
Market Cap2.92B
Analysts83.2
Price Target15.3 (32.7%)
Short Float %11.23%
Short Ratio4.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-581.75%
Min EPS beat(2)-1186.76%
Max EPS beat(2)23.27%
EPS beat(4)2
Avg EPS beat(4)-403.96%
Min EPS beat(4)-1186.76%
Max EPS beat(4)564.64%
EPS beat(8)2
Avg EPS beat(8)-245.45%
EPS beat(12)3
Avg EPS beat(12)-199.81%
EPS beat(16)4
Avg EPS beat(16)-161.92%
Revenue beat(2)0
Avg Revenue beat(2)-1.89%
Min Revenue beat(2)-2.01%
Max Revenue beat(2)-1.76%
Revenue beat(4)0
Avg Revenue beat(4)-1.67%
Min Revenue beat(4)-2.01%
Max Revenue beat(4)-0.92%
Revenue beat(8)1
Avg Revenue beat(8)-1.09%
Revenue beat(12)3
Avg Revenue beat(12)-0.04%
Revenue beat(16)7
Avg Revenue beat(16)1.52%
PT rev (1m)2.27%
PT rev (3m)20.6%
EPS NQ rev (1m)-34.41%
EPS NQ rev (3m)49.82%
EPS NY rev (1m)-43%
EPS NY rev (3m)-1856.86%
Revenue NQ rev (1m)0.5%
Revenue NQ rev (3m)7.82%
Revenue NY rev (1m)0.47%
Revenue NY rev (3m)3.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 92.83
P/S 5.22
P/FCF N/A
P/OCF 54.74
P/B 4.05
P/tB 10.5
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)0.12
Fwd EY1.08%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)0.21
OCFY1.83%
SpS2.21
BVpS2.85
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.39%
ROE -10.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.57%
FCFM N/A
ROA(3y)-14.16%
ROA(5y)-22.16%
ROE(3y)-19.14%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 117.79%
Cap/Sales 13.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.36
Quick Ratio 2.36
Altman-Z 7.38
F-Score6
WACC9.3%
ROIC/WACCN/A
Cap/Depr(3y)73.83%
Cap/Depr(5y)N/A
Cap/Sales(3y)12.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
EPS Next Y30.31%
EPS Next 2Y56.84%
EPS Next 3Y44.95%
EPS Next 5YN/A
Revenue 1Y (TTM)25.76%
Revenue growth 3Y24.82%
Revenue growth 5YN/A
Sales Q2Q%24.38%
Revenue Next Year26%
Revenue Next 2Y21.49%
Revenue Next 3Y19.99%
Revenue Next 5Y16.61%
EBIT growth 1Y-30.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year384.04%
EBIT Next 3Y88.5%
EBIT Next 5Y54.25%
FCF growth 1Y71.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y322.19%
OCF growth 3YN/A
OCF growth 5YN/A